Nik Subramanian

Working on finding drugs for serious, untreated diseases, using Machine Learning. Cofounder at Kantify.

[Kantify @kantify]

Kantify is excited to report its joint progress with @HopkinsMedicine on AI for prostate cancer drug discovery.
While a traditional small molecule discovery screening requires testing 20,000 to 100,000 molecules to find 1 hit, we have tested only 5 molecules to validate... 4.

[Kantify @kantify]

[News] AI unveils targets of drugs, starting with Viagra 📣
We are proud to announce today that our AI technology, Sapian, has been leveraged to predict the hidden side of known drugs.

[Ségolène Martin @Segozone]

Today we release our inaugural White Paper on the use of AI to predict the unknown off-targets of small molecules. We start with a known suspect of repurposing, aka Sildenafil / Viagra.
Discover below how we use AI to predict *novel* off targets of Viagra!

[Kantify @kantify]

[Announcement]
We have known for a while now that it was high time to rename our AI platform for drug discovery.
We unveil this new name today!

[Nik Subramanian @NikSubramanian]

@SimonDBarnett @dawallach Most people are trying incremental approaches with molecules, which work... incrementally. We've got solid evidence that orthogonal approaches for small molecules do yield giant steps forward ;)

[Kantify @kantify]

Today, Kantify's CTO Nik Subramanian presented at REXPO, the conference on drug repurposing, some of our novel findings on using Artificial Intelligence to find novel therapeutics targets and drugs for rare cancers! Exciting times.

[Nik Subramanian @NikSubramanian]

More promising news on this front: the drugs we identified seem highly effective in multiple different types of sarcomas. This further validates our theory that rare cancers share common weaknesses we can exploit in order to treat, and hopefully cure patients with these diseases.

[Nik Subramanian @NikSubramanian]

Very proud of Dr. @MayaJeitany presenting our groundbreaking collaboration at @myESMO in Lugano. In just 6 months, we've discovered 8 new drug targets and 7 novel repurposable drugs in most (all?) types of liposarcoma, rare cancers with high unmet need. More validations soon!

[Dreams EU Project @DreamsPjt_EU]

🚀 Exciting news!

@IStemFrance and @kantify, key partners of the DREAMS Project, are joining the 3rd International #RExP024 Conference in Munich on June 4-5!

A special thanks to @REPO4EU for their invaluable initiative. 🙌➡️ https://t.co/BW1kk0PrSJ

[Nik Subramanian @NikSubramanian]

@CanaudLab @ERC_Research @hopital_necker @chudequebec Continuing to make a life-changing impact on patients' lives - congratulations @CanaudLab

[Patrick Walters @wpwalters]

New Practical Cheminformatics Post, "Generative Molecular Design Isn't As Easy As People Make It Look", https://t.co/alCGUvsCDO

[Nik Subramanian @NikSubramanian]

We created an obesity crisis and resolved it with a single pill, all within 50 years. Human ingenuity is pretty remarkable.

[Eric Topol @EricTopol]

The GLP-1 family of drugs have exceeded all expectations, beyond diabetes and obesity.
Now there's a pre-clinical GLP-1 and NMDA dual receptor drug with many enhanced features that could prove to be another step forward
@Nature
https://t.co/UAaJM2o15n
https://t.co/qZ9DzPxMjq
@DarleenSandoval @ClemmensenC

[Nik Subramanian @NikSubramanian]

Using AI together with patient-derived stem cells significantly accelerates the discovery of treatments for rare diseases. Emilie Pellier and Dr. Miagoux (I-Stem) presented our (successful!) project at #Myology2024 to find treatments for LGMDR2, a rare neuromuscular disease.

[Nik Subramanian @NikSubramanian]

Measuring the effectiveness of drugs for neurological disorders is hard, but we're making progress! Mathijs Van Der Lei of @UAntwerpen recently presented how Kantify uses a new assay and AI to measure if drugs induce subtle changes in the natural behavior of diseased mice.

[Nik Subramanian @NikSubramanian]

We finally managed to synthesize this drug in a very pure form (and good news - it's still as effective). The chemistry side of the project has really required herculean efforts - thank you to my team and our partners for your grit.

[Nik Subramanian @NikSubramanian]

We got in vitro results today that show that we've found a first-in-class, potent drug that we hope will be able to treat a wide variety of cancers. Took us a couple of months (v. ~3-10 years usually) and tested just 30 compounds (v. 100k+). Still work to do, but screw cancer.

[Adam Feuerstein ✡️ @adamfeuerstein]

FDA approves Enhertu for all HER-2 positive solid tumors. $DSNKY $AZN

That's a bit of history - the first ADC granted a tumor-agnostic label.

https://t.co/pkpPNiMb1U

[Nik Subramanian @NikSubramanian]

@kantify @Nico_Maignan Congrats @Nico_Maignan ;) We're lucky to have you - looking forward to seeing you lead Kantify to the next big milestones!

[Kantify @kantify]

We are thrilled to announce that the brilliant Nicolas Maignan has joined the Kantify Executive Team in quality of Chief Operating Officer (COO). Join us in congratulating @Nico_Maignan 👏👏

[Nik Subramanian @NikSubramanian]

Our brilliant colleague Caio Hudson Queiroz de Souza just clinched his first co-authorship in @NatureMedicine - read more about the clinical trial he helped lead here: https://t.co/F52C6fF7qo

[Nik Subramanian @NikSubramanian]

Very proud of Dr. @MayaJeitany presenting our groundbreaking collaboration at @myESMO in Lugano. In just 6 months, we've discovered 8 new drug targets and 7 novel repurposable drugs in most (all?) types of liposarcoma, rare cancers with high unmet need. More validations soon!

[Kantify @kantify]

The Belgian federation of the biopharmaceutical industry, https://t.co/MdJCIUIWvN, invited us this week to contribute to its panel discussion on Artificial Intelligence in Healthcare.
👉 Read more in this article https://t.co/8qf3vCgBQj